ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO033

Contrast-Induced AKI and Adverse Clinical Outcomes Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Yang, Yi, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, Hubei, China, Wuhan, China
  • Ge, Shuwang, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
  • Xu, Gang, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, China
Background

Recent studies have shown associations between contrast-induced acute kidney injury (CI-AKI), in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), and increased risk of adverse clinical outcomes in ACS patients undergoing PCI; however, the estimates are inconsistent and vary widely.

Methods

EMBASE, PubMed, Web of ScienceTM and Cochrane Library databases were systematically searched from inception to December 16, 2016 for cohort studies assessing the association between CI-AKI and any adverse clinical outcomes in ACS patients treated with PCI. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CI) of these outcomes. Heterogeneity was explored by subgroup analyses.

Results

We identified 1857 articles in electronic search, of which 23 (n=33080) were included. Our meta-analysis revealed that CI-AKI significantly increased the risk of all-cause mortality (18 studies; n= 28367; RR=3.16, 95% CI 2.52–3.97; I2 =56.9%), short-term all-cause mortality (9 studies; n=13895; RR=5.55, 95% CI 3.53–8.73; I2 =60.1%), major adverse cardiac event(7 studies; n=19841; RR=1.49, 95% CI: 1.34–1.65; I2=0), major adverse cardiovascular and cerebrovascular event (3 studies; n=2768; RR=1.86, 95% CI: 1.42–2.43; I2=0) and stent restenosis (3 studies; n=130678; RR=1.50, 95% CI: 1.24–2.81; I2=0), respectively, in ACS patients undergoing PCI. Subgroup analyses showed the study design, sample size and prevalence of CI-AKI might have effect on pooled RR.

Conclusion

CI-AKI may be a prognostic marker of adverse outcomes in ACS patients undergoing PCI. More attention should be paid to diagnosis and management of CI-AKI.